Please contact us for more information or to learn if you are eligible to participate.
The primary objective of this study is o evaluate whether early treatment with venetoclax and obinutuzumab (V-O) extends overall survival (OS) compared with delayed treatment with V-O in highrisk (chronic lymphocytic leukemia [CLL] international prognostic indicator [CLLIPI] ≥4 or complex cytogenetics), newly diagnosed asymptomatic CLL/SLL patients
Jose Cruz, MD
National Cancer Institute (NCI)
Type of Trial